Since eosinopenia has been a biomarker for the severity of COVID-19 [43], eosinophil depletion induced by anti-IL5 and anti-IL5 receptor blocking monoclonal antibodies raises concern in patients and their treating physicians, despite the lack of evidence for increased risk of COVID-19 in asthmatics treated with mepolizumab, reslizumab or benralizumab [21]. The gene discussed is IL5; the disease is COVID-19.